Phoenix Life Sciences International Limited
PLSI · OTC
2/28/2019 | 2/28/2018 | 2/28/2017 | 2/29/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.14 | 0.00 | 0.00 |
| FCF Yield | -234.15% | -0.06% | -33.95% | -166.59% |
| EV / EBITDA | -0.07 | -2,536.50 | -10.90 | -0.91 |
| Quality | ||||
| ROIC | -30.24% | 0.08% | 6.41% | 95.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 67.77% |
| Cash Conversion Ratio | 0.28 | 0.01 | 0.08 | 0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | – |
| Free Cash Flow Growth | -187,679.48% | 97.71% | 91.20% | 80.18% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | -905.86 | -9.25 | -0.52 |
| Interest Coverage | -61.93 | -0.01 | -0.26 | -2.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -26,594.20 |